You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Recent results from the firm's case-control study cohort showed overall sensitivity of about 50 percent but higher performance for a subset of high-mortality cancers.
The results represent a significant improvement over currently used screening tools and are spurring renewed LDT commercialization and regulatory submission efforts.
The company reported RMB133.9 million (US$20.5 million) for the quarter, up from RMB102.9 million in the same period of 2019.
BioMark Diagnostics has been collaborating on the test with the Metabolomics Innovation Centre at the University of Alberta since early 2015.
The company is collaborating with the University of Leeds under a new grant, aiming to collect prospective validation and economic data that could support clinical adoption.
Despite challenges related to the coronavirus pandemic, the Chinese precision oncology firm reported total quarterly revenues of RMB131.7 million ($20.2 million).
The company plans to publish new data on clinical sensitivity and specificity and has initiated multiple studies investigating new use cases.
The company had been working to expand its retrospective data over the last year and half and is now readying to move forward with prospective studies.
The company intends to develop its fragmentomic approach for early cancer detection both in individual tumor types and for multi-cancer screening.
Backed by large public companies and growing prospective data, the first molecular blood tests to screen for multiple cancers are approaching commercialization.